About this Presentation
This presentation will provide an overview of phosphate metabolism and the biochemical mechanism of hypophosphastaemia after intravenous iron carboxymaltose (FCM) infusions, and outline the clinical presentations of hypophosphataemia, how common it is and the clinical risk factors to assist with testing the right patient for the condition.
Finally, the presentation will explain how to prevent and treat this condition by using alternative forms of iron infusions or active forms of vitamin D (calcitriol) and phosphate supplements.
About the Expert
Prof Peter Ebeling AO
Professor Peter Ebeling AO is Head of the Department of Medicine in the School of Clinical Sciences at Monash Health. He was also inaugural Director of the Australian Institute of Musculoskeletal Science (AIMSS).
Professor Ebeling was Associate Editor of Journal of Bone and Mineral Research from 2008-2012. He currently serves on the Editorial Board of Osteoporosis International and is Editor of Clinical Endocrinology (Oxf) and is Editor-in-Chief of JBMR Plus. He is Medical Director of Osteoporosis Australia; Board Member, International Osteoporosis Foundation; Past-President, Endocrine Society of Australia; Past-President of the Australian and New Zealand Bone and Mineral Society; and Councillor, American Society of Bone and Mineral Research.
